-
If your facility provides comprehensive sexually transmitted disease care for men who have sex with men (MSM), be sure to incorporate new guidance from the Centers for Disease Control and Prevention (CDC) regarding gonorrhea and chlamydia testing.
-
-
Women who want a permanent form of birth control now have a new option. The Food and Drug Administration (FDA) has approved the Adiana permanent contraception system, manufactured by Hologic of Bedford, MA.
-
Findings from new research may aid clinicians in identifying women who are likely to gain weight while using depot medroxyprogesterone acetate (DMPA, Depo Provera). Research indicates that DMPA users whose weight increased by 5% within the first six months of use are at risk of continued, excessive weight gain.
-
With the wide array of birth control options available today, are adolescents still relying on coitus interruptus? Results of a 2009 study indicate that clinicians should not consider use of contraceptive withdrawal infrequent among teens.
-
After taking the necessary diagnostic steps, the results are clear: The patient sitting in front of you needs to be treated for bacterial vaginosis (BV). The most common vaginal infection in women of childbearing age, women with BV may present with a white or gray discharge, odor, pain, or burning during urination. Symptoms aren't always present, though. More than 50% of women with BV may be asymptomatic.
-
Two new programs have been announced by Merck & Co. to help confirm patients' insurance coverage and address providers' reimbursement concerns regarding Gardasil, the quadrivalent human papillomavirus (HPV) vaccine.
-
The FDA has approved a single-dose formulation of Plan B, the emergency contraceptive previously available in a two-tablet dose.
-
Two papers presented at the recent American Society of Clinical Oncology (ASCO) have brought to light to potential serious drug interaction between tamoxifen and several commonly used SSRI antidepressants.
-
The FDA has approved prasugrel, a new oral antiplatelet agent for use in preventing thrombosis in patients with acute coronary syndrome who are to be managed by angioplasty.
